Inscrição na biblioteca: Guest

Experimental Approaches for Eliminating Latent HIV

Volume 6, Edição 1-2, 2015, pp. 91-99
DOI: 10.1615/ForumImmunDisTher.2016015242
Get accessGet access

RESUMO

Antiretroviral therapy (ART) can reduce HIV viral loads to undetectable levels and prevent disease progression. However, HIV persists in rare cellular reservoirs within ART-treated patients and rapidly reemerges if ART is stopped. Latently infected CD4+ T cells represent a major reservoir of HIV that persists during ART. Therefore, a cure for HIV must include methods that either permanently inactivate or eliminate latent virus. Experimental methods under investigation for eliminating latently infected cells include transplantation/gene therapy approaches intended to deplete the infected cells and replace them with HIV-resistant ones, and DNA editing strategies that are capable of damaging or excising non-expressing HIV proviruses. Alternatively, "activation-elimination", also known as "shock and kill", approaches aim to induce expression of latent virus, allowing the virus to be eliminated by viral cytopathic effects, immune effector mechanisms, or additional cells/antibodies that specifically target and kill cells expressing HIV proteins. Here, we describe these experimental approaches for eliminating latent HIV along with other recent advances in HIV cure research.

Palavras-chave: activation, latency, reservoir
CITADO POR
  1. Cao Shijie, Woodrow Kim A., Nanotechnology approaches to eradicating HIV reservoirs, European Journal of Pharmaceutics and Biopharmaceutics, 138, 2019. Crossref

  2. Kim Youry, Anderson Jenny L., Lewin Sharon R., Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV, Cell Host & Microbe, 23, 1, 2018. Crossref

  3. Hashemi Pargol, Sadowski Ivan, Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens, Medicinal Research Reviews, 40, 3, 2020. Crossref

  4. Marsden Matthew D., Benefits and limitations of humanized mice in HIV persistence studies, Retrovirology, 17, 1, 2020. Crossref

  5. Marsden Matthew D., Zack Jerome A., Humanized Mouse Models for Human Immunodeficiency Virus Infection, Annual Review of Virology, 4, 1, 2017. Crossref

  6. Marsden Matthew D., Wu Xiaomeng, Navab Sara M., Loy Brian A., Schrier Adam J., DeChristopher Brian A., Shimizu Akira J., Hardman Clayton T., Ho Stephen, Ramirez Christina M., Wender Paul A., Zack Jerome A., Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents, Virology, 520, 2018. Crossref

  7. Marsden Matthew D, Zack Jerome A, HIV cure strategies: a complex approach for a complicated viral reservoir?, Future Virology, 14, 1, 2019. Crossref

  8. Kwaa Abena K. R., Talana Chloe A. G., Blankson Joel N., Silvestri Guido, Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8 + T Cells , Journal of Virology, 93, 3, 2019. Crossref

  9. Kim Jocelyn T., Zhang Tian-Hao, Carmona Camille, Lee Bryanna, Seet Christopher S., Kostelny Matthew, Shah Nisarg, Chen Hongying, Farrell Kylie, Soliman Mohamed S. A., Dimapasoc Melanie, Sinani Michelle, Blanco Kenia Yazmin Reyna, Bojorquez David, Jiang Hong, Shi Yuan, Du Yushen, Komarova Natalia L., Wodarz Dominik, Wender Paul A., Marsden Matthew D., Sun Ren, Zack Jerome A., Latency reversal plus natural killer cells diminish HIV reservoir in vivo, Nature Communications, 13, 1, 2022. Crossref

  10. Sigalov Alexander B., SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale, Biochimie, 195, 2022. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain